Stock CBIO CATALYST BIOSCIENCES
Add to a list
To use this feature you must be a member
Log inSign up

Financials Catalyst Biosciences

Equities

CBIO

US14888D2080

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
17.11 USD +4.78% Intraday chart for Catalyst Biosciences +10.32% +123.09%
2023 Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index CI
2023 Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction. CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 79.3 94.27 82 139.4 28.71 16.61
Enterprise Value (EV) 1 51.94 -25.86 6.935 61.73 -15.76 -5.017
P/E ratio -1.83 x -2.94 x -1.48 x -2.15 x -0.32 x -2.02 x
Yield - - - - - -
Capitalization / Revenue 77.9 x 15,711 x - 6.66 x 3.91 x 20.9 x
EV / Revenue 51 x -4,310 x - 2.95 x -2.15 x -6.32 x
EV / EBITDA -2.4 x 0.77 x -0.12 x -1.08 x 0.19 x 0.17 x
EV / FCF 23 x 1.75 x -0.29 x -1.78 x 0.32 x 0.36 x
FCF Yield 4.35% 57% -349% -56% 310% 281%
Price to Book 2.7 x 0.79 x 1.2 x 1.83 x 0.7 x -0.92 x
Nbr of stocks (in thousands) 388 797 803 1,473 2,094 2,099
Reference price 2 204.6 118.3 102.1 94.65 13.71 7.912
Announcement Date 3/19/18 3/8/19 2/20/20 3/4/21 3/31/22 3/30/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 1.018 0.006 - 20.95 7.338 0.794
EBITDA 1 -21.65 -33.57 -57.13 -57.23 -83.44 -29.17
EBIT 1 -21.82 -33.72 -57.28 -57.37 -83.73 -29.4
Operating Margin -2,143.61% -562,033.33% - -273.87% -1,140.99% -3,702.27%
Earnings before Tax (EBT) 1 -21.56 -30.06 -55.18 -56.24 -87.93 -7.894
Net income 1 -21.56 -30.06 -55.18 -56.24 -87.93 -8.242
Net margin -2,117.98% -500,916.67% - -268.48% -1,198.32% -1,038.04%
EPS 2 -111.8 -40.20 -68.95 -43.99 -43.05 -3.919
Free Cash Flow 1 2.257 -14.75 -24.23 -34.6 -48.89 -14.12
FCF margin 221.73% -245,804.17% - -165.15% -666.21% -1,778.02%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/19/18 3/8/19 2/20/20 3/4/21 3/31/22 3/30/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 27.4 120 75.1 77.7 44.5 21.6
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 2.26 -14.7 -24.2 -34.6 -48.9 -14.1
ROE (net income / shareholders' equity) -92.1% -39.9% -58.6% -77.9% -150% -31.3%
ROA (Net income/ Total Assets) -35.2% -25.6% -32% -37.1% -69.5% -43.7%
Assets 1 61.34 117.2 172.2 151.7 126.5 18.87
Book Value Per Share 2 75.90 151.0 85.10 51.60 19.60 -8.620
Cash Flow per Share 2 35.70 39.20 19.10 20.60 21.20 8.610
Capex 1 0.02 0.38 0.06 0.27 0.84 -
Capex / Sales 2.26% 6,266.67% - 1.27% 11.43% -
Announcement Date 3/19/18 3/8/19 2/20/20 3/4/21 3/31/22 3/30/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. CBIO Stock
  4. Financials Catalyst Biosciences